Eidos Therapeutics, which is developing a novel oral therapy for rare neurodegenerative diseases, announced terms for its IPO on Friday.
The San Francisco, CA-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. Insiders intend to purchase $50 million worth of shares in the offering. At the midpoint of the proposed range, Eidos Therapeutics would command a fully diluted market value of $583 million.
Eidos Therapeutics was founded in 2013 and plans to list on the Nasdaq under the symbol EIDX. J.P. Morgan and BofA Merrill Lynch are the joint bookrunners on the deal. It is expected to price during the week of June 18, 2018.
